Online citations, reference lists, and bibliographies.
← Back to Search

Recent Advances In Vaccine Adjuvants

M. Singh, D. O'hagan
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
New generation vaccines, particularly those based on recombinant proteins and DNA, are likely to be less reactogenic than traditional vaccines but are also less immunogenic. Therefore, there is an urgent need for the development of new and improved vaccine adjuvants. Adjuvants can be broadly separated into two classes based on their principal mechanisms of action: vaccine delivery systems and immunostimulatory adjuvants. Vaccine-delivery systems generally are particulate (e.g., emulsions, microparticles, iscoms, and liposomes)and function mainly to target associated antigens into antigen-resenting cells. In contrast, immunostimulatory adjuvants are derived predominantly from pathogens and often represent pathogen-ssociated molecular patterns (e.g., lipopolysaccaride, monophosphoryl lipid A, CpG DNA), which activate cells of the innate immune system. Recent progress in innate immunity is beginning to yield insight into the initiation of immune responses and the ways in which immunostimulatory adjuvants may enhance this process. The discovery of more potent adjuvants may allow the development of prophylactic and therapeutic vaccines against cancers and chronic infectious diseases. In addition, new adjuvants may also allow vaccines to be delivered mucosally.
This paper references
10.1038/NBT1197-1280
A protein particle vaccine containing multiple malaria epitopes
S. Gilbert (1997)
10.1038/386410A0
Biologically erodable microspheres as potential oral drug delivery systems
E. Mathiowitz (1997)
10.1385/1-59259-083-7:327
Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction
J. Neidleman (2000)
10.1016/0167-5699(90)90034-7
Immunological adjuvants: a role for liposomes.
G. Gregoriadis (1990)
10.1021/JS990011U
Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.
J. Muderhwa (1999)
10.1021/JM990222B
3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities.
D. Johnson (1999)
10.1128/IAI.65.10.4288-4298.1997
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins.
P. Giannasca (1997)
10.1016/S0264-410X(97)00153-9
Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant.
M. Marchetti (1998)
immune mechanisms and treatment of autoimmune diseases
H. L. Weiner. Oral tolerance (1997)
A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].
A. Langenberg (1995)
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env , Gag , and Pro in combination with rgp 120
I. Srivastava Cherpelis (2001)
10.1128/IAI.67.11.5892-5897.1999
Intranasal Immunization with Pneumococcal Polysaccharide Conjugate Vaccines with Nontoxic Mutants of Escherichia coliHeat-Labile Enterotoxins as Adjuvants Protects Mice against Invasive Pneumococcal Infections
H. Jakobsen (1999)
10.1128/IAI.65.1.331-334.1997
Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop.
V. Giannelli (1997)
10.1128/JVI.75.3.1547-1550.2001
DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques
S. Cherpelis (2001)
10.1023/A:1007594911541
Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
T. Menegon (2004)
a role for liposomes
G. Gregoriadis. Immunologic adjuvants (1990)
10.1016/0923-2494(92)80058-S
Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity.
G. L. Gustafson (1992)
Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
R. Smith (1999)
10.1111/j.1749-6632.1993.tb44016.x
Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl‐Tn Conjugated to KLH Plus Detox Adjuvant
B. M. Longenecker (1993)
10.1126/SCIENCE.8493576
Protection against vaginal SIV transmission with microencapsulated vaccine.
P. Marx (1993)
10.1084/JEM.187.7.1123
Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity
M. Giuliani (1998)
Cationic microparticles are an effec Vaccine Adjuvants 723 tive delivery system for immune stimulatory CpG DNA
M. Singh (2001)
Vaccine design : the subunit and adjuvant approach
M. F. Powell (1995)
10.1023/A:1011053931523
The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Delivery
M. Briones (2004)
10.1016/S0264-410X(00)00433-3
Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
M. Conway (2001)
10.1038/sj.gt.3301347
Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells
K. Denis-Mize (2000)
10.1016/0264-410X(95)00077-E
Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function.
S. Soltysik (1995)
Design , characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split
G. R. Matyas (2001)
10.1016/S0140-6736(05)79439-3
Optimism over vaccines administered via mucosal surfaces
M. Levine (1998)
10.1016/0304-4157(92)90004-T
Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens.
C. Alving (1992)
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine : Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th 1 and Th 2 Cells
E. Ryan (1999)
The intestinal uptake of particles and the implications for drug and antigen delivery.
D. O'hagan (1996)
MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
C. Simmons (1999)
10.1038/35047123
A Toll-like receptor recognizes bacterial DNA
H. Hemmi (2000)
10.1023/A:1016030202104
Lectin-bearing Polymerized Liposomes as Potential Oral Vaccine Carriers
Hongming Chen (2004)
10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y
Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
M. Gagliardi (2000)
10.4049/jimmunol.164.12.6276
The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects1
L. Ågren (2000)
10.1126/SCIENCE.282.5388.476
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.
R. Wang (1998)
10.1016/S0264-410X(99)00138-3
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly.
S. de Donato (1999)
safety and immunogenicity
A. G. Langenberg (1995)
10.1086/318523
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
L. Corey (2001)
10.1385/1-59259-083-7:239
The ISCOM™ Technology
K. Lövgren-Bengtsson (2000)
evidence for viral clearance
E. J. Verschoor (1999)
10.1002/(SICI)1096-9098(199806)68:2<122::AID-JSO10>3.0.CO;2-4
Use of cellular and cytokine adjuvants in the immunotherapy of cancer
M. Salgaller (1998)
10.1016/S0168-3659(00)00330-8
A novel bioadhesive intranasal delivery system for inactivated influenza vaccines.
M. Singh (2001)
Induction of mucosal and systemic immune responses by immu Vaccine Adjuvants 725 nization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles
K. J. Maloy (1994)
10.1016/S0264-410X(97)00254-5
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.
S. Thoelen (1998)
Cytokines as immunologic adjuvants
A. W. Heath (1995)
10.1086/317923
Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant.
M. Ugozzoli (2001)
10.1038/NBT0298-153
Improving protein therapeutics with sustained-release formulations
S. D. Putney (1998)
10.1093/INFDIS/170.5.1288
Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
J. Kahn (1994)
10.1016/S0264-410X(96)00150-8
Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.
G. Lawrence (1997)
10.1517/13543784.7.9.1475
QS-21: a water-soluble triterpene glycoside adjuvant.
C. Kensil (1998)
10.1016/S0169-409X(98)00012-X
Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines.
Gupta (1998)
Saponins as vaccine adjuvants.
Kensil Cr (1996)
Antigen delivery systems: nonliving microparticles, liposomes, cochleates, and ISCOMS
S. M. Michalek (1999)
THE INTESTINAL UPTAKE OF PARTICLES AND THE IMPLICATIONS FOR DRUG AND ANTIGEN DELIVERY
O'Hagan Dt (1996)
10.1128/IAI.63.8.2880-2885.1995
Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres.
J. Tseng (1995)
10.1128/JVI.73.4.3292-3300.1999
Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance
E. Verschoor (1999)
10.1006/SMIM.1998.0143
An innate sense of danger.
P. Matzinger (1998)
10.1016/S0165-2478(97)86163-9
Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
L. Ågren (1997)
10.1056/NEJM199907223410410
DNA vaccines--designer vaccines for the 21st century.
R. Seder (1999)
10.1128/IAI.69.2.1151-1159.2001
The Common Vaccine Adjuvant Aluminum Hydroxide Up-Regulates Accessory Properties of Human Monocytes via an Interleukin-4-Dependent Mechanism
M. Ulanova (2001)
10.1016/S0169-409X(98)00011-8
Development of adjuvant-active nonionic block copolymers.
Todd (1998)
10.1016/S0264-410X(01)00142-6
Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.
D. Waite (2001)
10.1128/IAI.64.2.489-494.1996
Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.
D. I. Jones (1996)
10.1038/82225
Transcutaneous immunization: A human vaccine delivery strategy using a patch
G. M. Glenn (2000)
10.1101/pdb.caut403
Freund's adjuvants.
E. Brown (1969)
10.1097/00002030-199310000-00003
Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses
S. Martin (1993)
10.1385/MB:19:2:169
Virus-like particles as vaccine adjuvants
S. Gilbert (2001)
10.1016/S0264-410X(01)00041-X
Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes.
J. Conlan (2001)
10.1016/S0264-410X(99)00088-2
A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.
T. Heineman (1999)
10.1016/S0264-410X(97)00076-5
Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.
I. Ling (1997)
10.1016/S0140-6736(97)09440-3
Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
S. Calarota (1998)
10.1016/S0264-410X(99)00388-6
A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
S. Mccormack (2000)
10.1128/IAI.64.3.974-979.1996
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant.
A. Di Tommaso (1996)
10.1093/INFDIS/174.6.1168
MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.
P. Traquina (1996)
10.1016/S0264-410X(00)00394-7
Detoxification of endotoxin by aluminum hydroxide adjuvant.
Y. Shi (2001)
10.1016/S0169-409X(98)00045-3
Microparticles and polymers for the mucosal delivery of vaccines.
O’Hagan (1998)
10.1016/0168-3659(96)01459-9
Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability
Hongming Chen (1996)
Action of saponins on biologic membranes
A. M. Glaueri (1962)
in seronegative Thais
F. Sinangil (2000)
10.1016/S0264-410X(97)00015-7
Immunogenicity and protectivity of a new liposomal hepatitis A vaccine.
F. Ambrosch (1997)
10.1159/000049504
A Th1-Inducing Adjuvant, MPL®, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines
A. Wheeler (2001)
10.1046/j.1365-2567.2001.01157.x
The identification of plant lectins with mucosal adjuvant activity
E. Lavelle (2001)
10.1615/CRITREVTHERDRUGCARRIERSYST.V12.I1.10
Biodegradable microspheres in drug delivery.
H. Okada (1995)
10.1128/IAI.59.9.2978-2986.1991
Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.
J. Eldridge (1991)
10.1016/S0169-409X(98)00014-3
Targeting immune response induction with cochleate and liposome-based vaccines.
Mannino (1998)
10.1016/0264-410X(94)00008-B
Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.
E. Cahill (1995)
Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response.
H. C. Yip (1999)
A phase I clinical trial of a multiepitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine
H. Toledo (2001)
in both young and old mice
G. Van Nest (1996)
Immunization of human HIVseronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses
S. J. Martin (1993)
10.1038/81153
Production of hepatitis B surface antigen in transgenic plants for oral immunization
L. Richter (2000)
Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen.
J. Brewer (1998)
10.1128/IAI.65.9.3520-3528.1997
Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.
S. Sasaki (1997)
10.1787/9789264054110-3-en
Current Status of the
G. J. Glass (1967)
10.1111/j.1600-065X.1997.tb00969.x
Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity
R. Zinkernagel (1997)
10.1128/JVI.72.6.4931-4939.1998
Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes
S. Sasaki (1998)
10.4049/jimmunol.164.3.1617
Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1
Gunther Hartmann (2000)
10.1111/j.1749-6632.2000.tb05343.x
Efficacy and Safety of New Adjuvants
J. Aucouturier (2000)
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA.
J. Messina (1991)
10.1016/S0264-410X(96)00159-4
Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles.
S. Challacombe (1997)
Past experiences and new directions
J. T. Ulrich (1995)
synthesis and immunostimulant activities
D. A. Johnson (1999)
Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. coli (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant
M. Ugozzoli (2001)
10.1016/S0264-410X(00)00343-1
Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres.
P. Johansen (2000)
Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant.
M. Yamamoto (1999)
10.1101/SQB.1989.054.01.003
Approaching the asymptote? Evolution and revolution in immunology.
C. Janeway (1989)
10.1016/S0264-410X(96)00073-4
In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.
R. K. Gupta (1996)
10.1385/1-59259-083-7:273
MPL® Immunostimulant: Adjuvant Formulations
J. T. Ulrich (2000)
10.1128/IAI.68.1.54-63.2000
Archaeosome Vaccine Adjuvants Induce Strong Humoral, Cell-Mediated, and Memory Responses: Comparison to Conventional Liposomes and Alum
L. Krishnan (2000)
10.1016/S0264-410X(00)00497-7
Immune responses to ISCOM formulations in animal and primate models.
A. Sjölander (2001)
10.1016/0168-3659(90)90133-E
Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches
J. Eldridge (1990)
Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes.
L. Klavinskis (1996)
10.1016/S0169-409X(98)00008-8
Aluminum compounds as vaccine adjuvants.
Gupta (1998)
10.1016/S0264-410X(98)00151-0
CpG motifs as immune adjuvants.
D. Klinman (1999)
10.1016/S0140-6736(94)92581-X
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
S. Straus (1994)
10.1016/0264-410X(93)90387-D
Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles.
D. O'hagan (1993)
10.1086/319215
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
C. Cunningham (2001)
10.1016/S0264-410X(96)00099-0
Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity.
D. Nixon (1996)
Immune responses to ISCOM((R)) formulations in animal and primate models. Vaccine
A. Sjolander (2001)
Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines
D. O’Hagan (2001)
containing MF 59 adjuvant
Y. E. McHugh Granoff (1999)
10.11501/3160149
Monophosphoryl Lipid A Enhances Both Humoral and Cell-Mediated Immune Responses to DNA Vaccination against Human Immunodeficiency Virus Type 1(一リン酸化リピドAによるヒト免疫不全ウイルス1型に対するDNAワクチンの液性および細胞性免疫応答の増強)
佐々木津 (1998)
Vaccine adjuvants : preparation methods and research protocols
D. O'hagan (2000)
10.7326/0003-4819-122-12-199506150-00001
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
A. Langenberg (1995)
Microparticles as oral vaccines
D. T. O’Hagan (1994)
10.1086/338448
Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol.
H. Cao (2002)
10.1211/0022357011775929
Tissue distribution of radioactivity following intranasal administration of radioactive microspheres
J. E. Eyles (2001)
Oral immunization with an antiidiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection
J. A. Whittum-Hudson (1996)
10.3109/08982100009031103
Virosomes as an Antigen Delivery System
T. Daemen (2000)
Safety and immunogenicity of a three-component bloodstage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine
B. Genton (2000)
10.1126/science.272.5258.50
The Instructive Role of Innate Immunity in the Acquired Immune Response
D. Fearon (1996)
Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.
K. Maloy (1994)
Biodegradable microparticles as controlled release antigen delivery systems.
D. O'hagan (1991)
10.1007/978-1-4615-1823-5_10
MF59. Design and evaluation of a safe and potent adjuvant for human vaccines.
G. Ott (1995)
10.1038/298347A0
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
P. Valenzuela (1982)
10.1128/IAI.65.5.1710-1715.1997
MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine.
D. Granoff (1997)
10.1038/374546A0
CpG motifs in bacterial DNA trigger direct B-cell activation
Arthur M. Krieg (1995)
10.1038/NM0598-607
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
C. Tacket (1998)
10.1128/JVI.73.9.7780-7786.1999
Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers
U. Glück (1999)
10.1128/IAI.67.9.4400-4406.1999
Genetically Detoxified Mutants of Heat-Labile Toxin from Escherichia coli Are Able To Act as Oral Adjuvants
G. Douce (1999)
10.1128/IAI.65.3.853-857.1997
Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.
K. Allaoui-Attarki (1997)
10.1073/PNAS.97.2.811
Cationic microparticles: A potent delivery system for DNA vaccines.
M. Singh (2000)
10.1073/PNAS.260497597
Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.
Y. Shi (2000)
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria
R. Wang (1998)
10.1016/0264-410X(95)00240-2
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.
D. A. Higgins (1996)
IscomT adjuvant - a promising adjuvant for influenza virus vaccines
J. Bates (1996)
10.1016/0264-410X(91)90295-H
Controlled release microparticles for vaccine development.
D. O'hagan (1991)
10.1016/0168-9525(87)90294-0
CpG islands as gene markers in the vertebrate nucleus
A. Bird (1987)
The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine
M. Briones (2001)
Saponins as vaccine adjuvants.
C. Kensil (1996)
10.1093/JNCI/72.4.955
Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.
T. Tokunaga (1984)
10.1023/A:1012153011884
Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat
N. Hussain (2004)
Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice.
D. Broide (1998)
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
A. Gringeri (1998)
10.1128/CDLI.8.3.652-657.2001
Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization
J. Barackman (2001)
10.1099/0022-1317-78-4-757
Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines.
G. Rimmelzwaan (1997)
10.1016/S0167-5699(97)01053-0
Oral tolerance: immune mechanisms and treatment of autoimmune diseases.
H. Weiner (1997)
10.1016/S0264-410X(00)00036-0
Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
B. Genton (2000)
10.1016/0264-410X(95)00184-3
Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
A. Moore (1995)
10.1124/JPET.300.2.655
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
L. Hawkins (2002)
10.1016/S0264-410X(99)00009-2
Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs.
D. O’Hagan (1999)
10.1038/NM0498-397
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
J. Schneider (1998)
10.1146/ANNUREV.IY.12.040194.005015
Tolerance, danger, and the extended family.
P. Matzinger (1994)
10.1016/S0264-410X(97)00288-0
Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids.
E. Relyveld (1998)
tency of a genetically toxoided mucosal adjuvant derived from the heat - labile enterotoxin of E . coli ( LTK 63 ) is not adversely affected by the presence of pre - existing immunity to the adjuvant
G. Santos Ugozzoli (2001)
Prospects for the development of new and improved vaccines through the use of microencapsulation technology
D. T. O’Hagan (1997)
10.1126/science.306.5705.2164b
Of Mice . . .
S. Simpson (2004)
10.1086/315022
A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
R. Pass (1999)
10.1128/IAI.67.12.6270-6280.1999
Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells
E. Ryan (1999)
10.1046/j.1365-2567.1997.00307.x
HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody
S. Toda (1997)
10.1128/IAI.65.12.4996-5002.1997
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection.
P. Ghiara (1997)
10.1016/0022-1759(86)90402-3
An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
A. Allison (1986)
10.1038/196952A0
Action of Saponin on Biological Cell Membranes
A. Bangham (1962)
10.1038/icb.1990.18
Influence of antigens and adjuvants on the production of gamma‐interferon and antibody by ovine lymphocytes
D. Emery (1990)
10.1016/S0168-3659(00)00226-1
Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.
J. Kazzaz (2000)
10.1038/35046108
Development of a preventive vaccine for Ebola virus infection in primates
N. Sullivan (2000)
10.1016/S0092-8674(00)80412-2
Innate Immunity: The Virtues of a Nonclonal System of Recognition
R. Medzhitov (1997)
10.1016/S0264-410X(00)00415-1
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
T. Evans (2001)
10.1128/JVI.75.19.9037-9043.2001
Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines
D. O'hagan (2001)
10.1016/S0264-410X(96)00266-6
Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.
D. I. Jones (1997)
10.1038/36014
Skin immunization made possible by cholera toxin
G. Glenn (1998)
Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.
S. Challacombe (1992)
Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
L. Ågren (1999)
Immune responses of mice and human breast cancer Vaccine Adjuvants 727 patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant
B. M. Longenecker (1993)
Biodegradable microspheres in drug
H. Okada (1995)
10.1016/S0167-5699(99)01523-6
Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.
R. Rappuoli (1999)
10.1038/40967
Seeking wisdom in innate immunity
D. Fearon (1997)
10.1073/PNAS.92.5.1644
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.
G. Douce (1995)
10.1128/IAI.63.4.1195-1200.1995
Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
R. Shahin (1995)
10.1128/IAI.65.7.2821-2828.1997
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.
G. Douce (1997)
10.1038/NM0198-043
Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
B. Agrawal (1998)
10.4049/jimmunol.166.5.3589
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
N. Polakos (2001)
10.1023/A:1012269226066
Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA
M. Singh (2004)
10.1128/IAI.68.10.5509-5516.2000
Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen
N. Childers (2000)
10.1086/315337
Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant.
R. Glueck (2000)
based on PLA / PLGA microspheres
M. Balusubramanian (2000)
netically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A 1 sub - unit
L. Ekman Agren (1997)
develop - ment
H. Jeffery (1991)
Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-coglycolide) microspheres
K. Allaoui-Attarki (1997)
G . Gregoriadis . Immunologic adjuvants : a role for liposomes
G. Wiedermann Ambrosch (1990)
10.1016/S0264-410X(97)00222-3
Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo.
N. Foster (1998)
10.1016/S0264-410X(99)00522-8
Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
D. O'hagan (2000)
10.1016/S0264-410X(97)00115-1
The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice.
D. Cataldo (1997)
10.1016/S1357-4310(96)10058-7
Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
D. O'hagan (1997)
10.1056/NEJM199701093360202
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
J. Stoute (1997)
10.1016/S0169-409X(98)00013-1
ISCOMs and other saponin based adjuvants.
Cox (1998)
Poly(lactide-coglycolide) microparticles for the development of single-dose controlled-release vacccines
D. T. O’Hagan (1998)
10.1016/S0264-410X(01)00111-6
A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
H. Toledo (2001)
10.1126/science.169.3950.1042
A Theory of Self-Nonself Discrimination
P. Bretscher (1970)
Sur la toxine et surranatoxine diphtheriques
G. Ramon (1924)
10.1016/S0264-410X(99)00421-1
A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais.
S. Nitayaphan (2000)
10.1073/PNAS.94.22.12059
Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
T. Goletz (1997)
10.1006/VIRO.1999.9765
Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).
F. Ennis (1999)
10.1046/j.1365-2567.1998.00441.x
Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses
Ugozzoli (1998)
10.1038/NM0398-365
Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
M. L. Hedley (1998)
10.1128/JVI.69.10.5929-5934.1995
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice.
R. Schirmbeck (1995)
10.1038/80538
Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice
D. Chen (2000)
10.1007/978-1-4615-1823-5_7
A compendium of vaccine adjuvants and excipients.
F. Vogel (1995)
10.1016/S0264-410X(97)00149-7
Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.
L. G. Payne (1998)
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine
S. Thoelen (1998)
10.1007/978-1-4615-1823-5_21
Monophosphoryl Lipid A as an Adjuvant
J. T. Ulrich (1995)
10.1016/S0264-410X(02)00076-2
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
R. Amara (2002)
10.1016/S0140-6736(00)04769-3
Trade systems in less-developed countries
J. Nicholson (2001)
10.1016/S0928-0987(01)00175-0
Oral vaccination in man using antigens in particles: current status.
D. Brayden (2001)
10.1016/S0264-410X(00)00386-8
Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine.
B. Guy (2001)
stability and bioavailability
H. Chen (1996)
10.1038/NM1096-1116
Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection
J. Whittum-Hudson (1996)
10.1128/IAI.63.5.1617-1623.1995
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.
B. Dickinson (1995)
10.1016/S0264-410X(98)00250-3
Lipopeptide particles as the immunologically active component of CTL inducing vaccines.
Ikuo Tsunoda (1999)
10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8
Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
T. Sparwasser (1998)



This paper is referenced by
10.1016/S0005-2736(02)00713-7
Monoclonal antibodies for the structural analysis of the Na+/H+ antiporter NhaA from Escherichia coli.
M. Venturi (2003)
10.1016/J.JCHROMB.2005.06.013
Separation and quantification of a novel two-component vaccine adjuvant.
Constantia Kritsch (2005)
10.1002/jps.21493
Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems.
S. Sharma (2009)
10.1080/10611860410001670044
Archaeosomes as Self-adjuvanting Delivery Systems for Cancer Vaccines*
L. Krishnan (2003)
10.1007/978-1-59259-745-1_4
Augmentation of Cell-Mediated Immunity to Virus
E. Woodahl (2004)
10.1016/J.VETIMM.2007.01.003
Adjuvant effect of green propolis on humoral immune response of bovines immunized with bovine herpesvirus type 5.
G. Fischer (2007)
10.1586/14760584.6.5.849
New adjuvants: EU regulatory developments
D. Sesardic (2007)
10.1007/978-1-4419-0540-6
Bioinformatics for immunomics
D. Flower (2010)
10.1016/j.ijpharm.2011.04.068
Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles.
Elodie Macho Fernandez (2012)
10.1016/J.VACCINE.2007.06.057
Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
G. Hui (2007)
10.1016/j.xphs.2016.03.026
Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems.
Keiya Muto (2016)
10.1016/j.actbio.2013.06.010
Size effect of amphiphilic poly(γ-glutamic acid) nanoparticles on cellular uptake and maturation of dendritic cells in vivo.
F. Shima (2013)
Vaccination de volontaires sains avec le vaccin contre la fièvre jaune afin de caractériser la réponse immunitaire protectrice
R. Therrien (2008)
10.1248/YAKUSHI.127.307
[Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine].
T. Akagi (2007)
10.1016/j.actbio.2013.12.036
Engineering vaccines and niches for immune modulation.
Alberto Purwada (2014)
10.15496/publikation-3983
Der Malaria-Impfstoffkandidat GMZ2 : Beurteilung der Sicherheit und der humoralen Immunantwort im Rahmen einer Phase-Ib-Studie in Gabun
Carolin Eva Treut (2015)
10.14800/PID.1259
Adjuvants in malaria vaccine development strategies: a review
Josiah Ogise (2016)
10.4236/WJV.2011.12007
Selection of Adjuvants for Enhanced Vaccine Potency
W. Wang (2011)
10.1016/J.VACCINE.2004.09.007
The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate--a revisit of the role of the hydrophile-lipophile balance (HLB) value.
Y. Yang (2005)
10.1016/J.IJPHARM.2007.04.030
Analysis of Quil A-phospholipid mixtures using drift spectroscopy.
P. Demana (2007)
UNIVERSIDADE FEDERAL DE PELOTAS Programa de Pós-Graduação em Biotecnologia Agrícola
G. Fischer (2007)
10.2174/156720109787048221
Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens.
A. Taghavi (2009)
10.1007/s11095-010-0241-4
Nanoparticle Delivery Systems in Cancer Vaccines
Yogita Krishnamachari (2010)
10.1016/j.rvsc.2012.05.011
Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice.
S. Okay (2012)
Immunostimulatory effects and delivery of oligodeoxynucleotides containing CpG motifs (CpG-ODN) in neonatal broiler chickens
Azita Joze Taghavi Shirazi (2007)
10.1128/9781555815851.CH19
Antimicrobial peptides as mucosal adjuvants.
Lindsey C Pingel (2007)
10.1002/JPS.20675
A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
Laura J. Peek (2007)
10.1016/J.VACCINE.2006.10.005
Immunomodulation produced by a green propolis extract on humoral and cellular responses of mice immunized with SuHV-1.
G. Fischer (2007)
10.7439/IJBR.V2I1.84
USE OF BIODEGRADABLE MICRO AND NANO-PARTICLES IN VACCINE DELIVERY
Mukty Sinha (2011)
10.1007/s12539-015-0279-4
Comparative Analysis of the Molecular Adjuvants and Their Binding Efficiency with CR1
B. Saranya (2015)
10.1016/j.ijpharm.2008.06.030
Immunomodulatory biomaterials.
S. Mallapragada (2008)
10.1002/jps.24256
Development of a high-throughput screening platform to study the adsorption of antigens onto aluminum-containing adjuvants.
Vanessa Jully (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar